Structures by: Bouhfid R.
Total: 35
I,C16.87H15.62NOS
I,C16.87H15.62NOS
RSC Adv. (2016) 6, 112 111472
a=7.4292(2)Å b=10.7679(2)Å c=20.5682(4)Å
α=90° β=90.0000(10)° γ=90°
I,C18H18NOS
I,C18H18NOS
RSC Adv. (2016) 6, 112 111472
a=7.7022(8)Å b=10.3394(11)Å c=11.3339(12)Å
α=97.090(4)° β=99.284(4)° γ=91.950(4)°
6,9-Dimethyl-7<i>H</i>-[1,2,4]triazolo[4,3-<i>b</i>][1,2,4]triazepin-8(9<i>H</i>)-one 0.40-hydrate
C7H9N5O,0.4(H2O)
Acta Crystallographica Section E (2015) 71, 1 o1-o2
a=11.4970(18)Å b=11.4527(18)Å c=14.867(2)Å
α=90.00° β=109.615(4)° γ=90.00°
Ethyl 6-chloro-2-ethoxyquinoline-4-carboxylate
C14H14ClNO3
Acta Crystallographica Section E (2019) 75, 6 912-916
a=14.2634(7)Å b=16.0124(7)Å c=13.7732(6)Å
α=90° β=117.748(2)° γ=90°
1-[(2,2-Dimethyl-1,3-dioxolan-4-yl)methyl]-2-(thiazol-4-yl)-1<i>H</i>-benzimidazole
C16H17N3O2S
Acta Crystallographica Section E (2015) 71, 12 o951-o952
a=9.3177(5)Å b=9.3786(6)Å c=9.5418(6)Å
α=78.739(4)° β=78.777(3)° γ=73.632(3)°
1-Benzyl-2-[1-(5-methyl-1H-pyrazol-3-yl)-2-phenylethyl]benzimidazole
C26H24N4
Acta Crystallographica, Section E (2005) 61, 8 o2718-o22719
a=10.244(5)Å b=10.601(5)Å c=11.404(5)Å
α=64.499(5)° β=74.587(5)° γ=89.556(5)°
4-Phenyl-2-(2-pyridylmethylsulfanyl)-3<i>H</i>-1,5-benzodiazepine
C21H17N3S
Acta Crystallographica Section E (2007) 63, 7 o3306-o3306
a=14.2995(3)Å b=8.7004(2)Å c=14.3851(4)Å
α=90.00° β=103.3370(10)° γ=90.00°
Ethyl 2-(2,3-dioxoindolin-1-yl)acetate
C12H11NO4
Acta Crystallographica Section E (2007) 63, 4 o1747-o1748
a=13.6433(6)Å b=4.9505(3)Å c=16.2899(8)Å
α=90.00° β=104.246(2)° γ=90.00°
6-Methyl-7,7,9-tripropargyl-7<i>H</i>-1,2,4- triazolo[4,3-<i>b</i>][1,2,4]triazepin-8(9<i>H</i>)-one
C15H13N5O
Acta Crystallographica Section E (2009) 65, 9 o2148
a=7.6710(2)Å b=8.2415(2)Å c=12.9619(3)Å
α=108.5100(10)° β=90.6590(10)° γ=114.7260(10)°
1-Benzyl-3-[(dimethylamino)methylene]-4-phenyl-1<i>H</i>- 1,4-benzodiazepin-2(3<i>H</i>)-one
C25H23N3O
Acta Crystallographica Section E (2009) 65, 9 o2160
a=8.9733(3)Å b=26.3103(7)Å c=9.9312(3)Å
α=90° β=115.6440(10)° γ=90°
7,9-Diallyl-6-methyl-7<i>H</i>-1,2,4-triazolo[4,3-<i>b</i>][1,2,4]triazepin-\ 8(9<i>H</i>)-one
C12H15N5O
Acta Crystallographica Section E (2009) 65, 9 o2152
a=7.4674(3)Å b=8.3398(3)Å c=20.2214(6)Å
α=90.00° β=95.174(2)° γ=90.00°
5-Methyl-3-[1-(2-pyridylmethyl)-1<i>H</i>-benzimidazol-2-ylmethyl]isoxazole
C18H16N4O
Acta Crystallographica Section E (2009) 65, 11 o2714-o2715
a=11.0761(2)Å b=8.65350(10)Å c=16.5920(3)Å
α=90.0° β=103.1360(10)° γ=90.0°
3-[2-(3-Methyl-2-oxo-1,2-dihydroquinoxalin-1-yl)ethyl]oxazolidin-2-one
C14H15N3O3
Acta Crystallographica Section E (2009) 65, 8 o2024-o2025
a=12.280(3)Å b=10.736(3)Å c=20.406(4)Å
α=90° β=102.320(10)° γ=90°
3-[2-(3-Methylquinoxalin-2-yloxy)ethyl]-1,3-oxazolidin-2-one
C14H15N3O3
Acta Crystallographica Section E (2010) 66, 5 o1050
a=6.9936(3)Å b=7.6916(3)Å c=13.3709(6)Å
α=86.649(2)° β=77.044(2)° γ=71.141(2)°
3-[2-(5<i>H</i>-Indolo[2,3-<i>b</i>]quinoxalin-5-yl)ethyl]-1,3-oxazolidin-2-one
C19H16N4O2
Acta Crystallographica Section E (2010) 66, 9 o2461
a=14.5565(4)Å b=5.8993(2)Å c=18.6434(6)Å
α=90.00° β=92.393(2)° γ=90.00°
4-Phenyl-9,12,15-trioxa-1,5,6,18- tetraazatetracyclo[16.6.1.0^2,6^.0^19,24^]pentaconta-2,4,19,21,23- pentaen-25-one
C24H26N4O4
Acta Crystallographica Section E (2009) 65, 10 o2493
a=13.3480(10)Å b=15.7850(10)Å c=11.0070(10)Å
α=90° β=102.6810(10)° γ=90°
1,3-Diallyl-2-methylbenzimidazolium bromide dihydrate
C14H17N2,Br,2H2O
Acta Crystallographica Section E (2009) 65, 10 o2321
a=13.2888(2)Å b=16.8763(2)Å c=7.38970(10)Å
α=90.00° β=109.7730(10)° γ=90.00°
3-[2-(2,3-dioxoindolin-1-yl)ethyl]-1,3-oxazolidin-2-one
C13H12N2O4
Acta Crystallographica Section E (2010) 66, 2 o454
a=7.1198(2)Å b=7.4694(2)Å c=12.0319(3)Å
α=83.338(2)° β=79.084(2)° γ=81.372(2)°
1,3-Dibenzyl-2-methylbenzimidazolium chloride
C22H21N2,Cl
Acta Crystallographica Section E (2010) 66, 2 o455
a=9.2539(2)Å b=9.4677(2)Å c=12.0984(3)Å
α=72.1390(10)° β=81.3760(10)° γ=64.6050(10)°
3-(Phenylimino)indolin-2-one
C14H10N2O
Acta Crystallographica Section E (2010) 66, 2 o453
a=20.1647(4)Å b=5.02230(10)Å c=21.8791(5)Å
α=90.00° β=90.00° γ=90.00°
<i>N</i>-(5-Phenyl-1<i>H</i>-pyrazol-3-yl)benzene-1,2-diamine
C15H14N4
Acta Crystallographica Section E (2010) 66, 4 o841
a=13.2357(8)Å b=5.8473(4)Å c=16.4039(10)Å
α=90.00° β=92.074(4)° γ=90.00°
1-Benzyl-3-[(dimethylamino)methylene]-4-phenyl-1<i>H</i>-1,5-benzodiazepine- 2(3<i>H</i>)-thione
C25H23N3S
Acta Crystallographica Section E (2010) 66, 5 o1019
a=26.4740(8)Å b=10.2366(2)Å c=16.5650(5)Å
α=90.00° β=106.1360(10)° γ=90.00°
1-Allyl-3-methyl-3',5'-diphenylspiro[quinoxaline- 2(1<i>H</i>),2'(3'<i>H</i>)-[1,3,4]thiadiazole]
C25H22N4S
Acta Crystallographica Section E (2010) 66, 12 o3227
a=7.92010(10)Å b=10.07130(10)Å c=13.6642(2)Å
α=78.2960(10)° β=81.2770(10)° γ=89.8260(10)°
1-allyl-3-phenylquinoxalin-2(1<i>H</i>)-one
C17H14N2O
Acta Crystallographica Section E (2011) 67, 11 o2990
a=15.123(2)Å b=7.0390(10)Å c=26.405(3)Å
α=90.00° β=95.250(10)° γ=90.00°
1,1'-Dibenzyl-5,5''-dichloro-1,1'',2,2''-tetrahydrodispiro[indole-3,7'- [6,9]diazatricyclo[7.3.0.0^2,6^]dodecane-8',3''-indole]-2,2''-dione
C38H34Cl2N4O2
Acta Crystallographica Section E (2012) 68, 6 o1664
a=12.0421(2)Å b=16.9085(2)Å c=15.9316(2)Å
α=90.00° β=101.2430(10)° γ=90.00°
1,1''-Bis(prop-2-en-1-yl)-1,1'',2,2''-tetrahydrodispiro[indole-3,7'- [6,9]diazatricyclo[7.3.0.0^2,6^]dodecane-8',3''-indole]-2,2''-dione
C30H32N4O2
Acta Crystallographica Section E (2012) 68, 6 o1637
a=14.9484(2)Å b=9.91730(10)Å c=17.5713(3)Å
α=90.00° β=111.1190(10)° γ=90.00°
5,5''-Dibromo-1,1''-bis(prop-2-en-1-yl)-1,1'',2,2''-tetrahydrodispiro[indole- 3,7'-[6,9]diazatricyclo[7.3.0.0^2,6^]dodecane-8',3''-indole]-2,2''-dione
C30H30Br2N4O2
Acta Crystallographica Section E (2012) 68, 6 o1638
a=14.1658(3)Å b=9.7203(2)Å c=20.6677(3)Å
α=90.00° β=100.0370(10)° γ=90.00°
Ethyl 2-(2-amino-5-methyl-1,2,4-triazolo[1,5-<i>a</i>]pyrimidin-7-yl)acetate
C10H13N5O2
Acta Crystallographica Section E (2012) 68, 1 o239
a=22.9635(4)Å b=7.74470(10)Å c=14.7017(3)Å
α=90.00° β=124.5740(10)° γ=90.00°
Bis[1-benzyl-2-(1,3-thiazol-4-yl)-1<i>H</i>-benzimidazole- κ^2^<i>N</i>^2^,<i>N</i>^3^]dichloridocobalt(II)
C34H26Cl2CoN6S2
Acta Crystallographica Section E (2013) 69, 1 m5-m6
a=10.1311(3)Å b=11.9582(4)Å c=14.2633(5)Å
α=76.033(3)° β=75.536(3)° γ=69.707(3)°
2-(3<i>H</i>-1,3-Benzothiazol-2-ylidene)propanedial
C10H7NO2S
Acta Crystallographica Section E (2011) 67, 9 o2260
a=8.3927(10)Å b=5.0972(8)Å c=20.739(2)Å
α=90.00° β=100.098(8)° γ=90.00°
2-[3-(1<i>H</i>-Benzimidazol-2-yl)propyl]-1-decyl-1<i>H</i>-benzimidazole
C27H36N4
Acta Crystallographica Section E (2011) 67, 9 o2544
a=38.5580(6)Å b=13.2052(2)Å c=9.9623(2)Å
α=90.00° β=95.3390(10)° γ=90.00°
1-Benzyl-3-methyl-3',5'-diphenylspiro[quinoxaline-2(1<i>H</i>),2'(3'<i>H</i>)- 1,3,4-thiadiazole]
C29H24N4S
Acta Crystallographica Section E (2012) 68, 1 o103
a=13.5441(2)Å b=14.8971(2)Å c=15.0149(2)Å
α=66.4310(10)° β=63.9210(10)° γ=65.2750(10)°
Bis(1-benzyl-1<i>H</i>-benzimidazole-κ<i>N</i>^3^)dichloridozinc
C28H24Cl2N4Zn
Acta Crystallographica Section E (2014) 70, 3 m94-m95
a=9.9819(4)Å b=10.0564(4)Å c=13.6641(6)Å
α=99.539(2)° β=92.087(2)° γ=99.122(2)°
2-(Benzylsulfanyl)-4-phenyl-3<i>H</i>-1,5-benzodiazepine
C22H18N2S
Acta Crystallographica Section E (2007) 63, 7 o3305-o3305
a=8.9633(2)Å b=8.4904(2)Å c=23.1997(5)Å
α=90.00° β=92.2060(10)° γ=90.00°
(<i>Z</i>)-1,3-diallyl-4-(2-oxopropylidene)-4,5-dihydro-1<i>H</i>-1,5- benzodiazepin-2(3<i>H</i>)-one
C18H20N2O2
Zeitschrift für Kristallographie - New Crystal Structures (2008) 223, 4 435
a=8.889(4)Å b=9.062(2)Å c=11.0870(10)Å
α=111.270(10)° β=94.91(2)° γ=104.80(3)°